Skip to main content
SpringerLink
Log in

Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment

  • Chapter
Chemo Fog

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 678))

Abstract

No standard has been established for neuropsychologic testing to identify and quantify chemotherapy-related cognitive impairment (CRCI). A number of issues exist related to the complexity of the phenomenon and lack of correlation between standardized objective tests and subjective tests by patient self-report. Review of the issues related to current neuropsychologic tests used to evaluate CRCI provides support for qualitative examination of patients’ lived experience in order to guide the development of more accurate tests.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Inves 2001; 19:812–820.

    Article  CAS  Google Scholar 

  2. Hess LM, Insel KC. Chemotherapy-related change in cognitive function: A conceptual model. Onco Nurs Forum 2007; 24:981–994.

    Article  Google Scholar 

  3. Nail LM. Cognitive changes in cancer survivors. American J Nurs 2006; 106(3):48–54.

    Article  Google Scholar 

  4. O’Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs 2003; 19(Supp 2):17–24.

    Article  PubMed  Google Scholar 

  5. Jansen C, Miaskowski C, Dodd M et al. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum 2005; 32(6):1151–1161.

    Article  PubMed  Google Scholar 

  6. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clinical Breast Cancer Supplement 2002; 3(Suppl 3):S91–S99.

    Article  Google Scholar 

  7. Ahles TA, Saykin A. Candidate mechanisms for chemotherapy-induced cognitive changes. Na Cancer Rev 2007; 7:192–201.

    Article  CAS  Google Scholar 

  8. Cimprich B, So H, Ronis DL et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 2005; 14:70–78.

    Article  PubMed  Google Scholar 

  9. Jansen C, Miaskowski C, Dodd M et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum 2007; 34:997–1005.

    Article  PubMed  Google Scholar 

  10. Brezden CB, Phillips KA, Abdollel M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:4175–4183.

    Google Scholar 

  11. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Oncol 2003; 21:4175–4183.

    Article  Google Scholar 

  12. Vardy J, Wong K, Yi QL et al. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14:1111–1118.

    Article  PubMed  Google Scholar 

  13. Klemp JR, Stanton AL, Kimler BF et al. Evaluating the effects of chemotherapy on cognitive function and quality of life in premenopausal women with breast cancer. Paper presented at the San Antonio Breast Cancer Sympsoium 2006; San Antonio.

    Google Scholar 

  14. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized longitudinal trial. Cancer 2004; 100:2292–2299.

    Article  CAS  PubMed  Google Scholar 

  15. Ahles TA, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clinical Breast Cancer Supplement 2002; S84–S90.

    Google Scholar 

  16. Hensley ML, Correa DD, Thaler H et al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 2006; 102:270–277.

    Article  CAS  PubMed  Google Scholar 

  17. Castellon SA, Ganz PA, Bower JE et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26:955–969.

    Article  PubMed  Google Scholar 

  18. Cull A, Hay C, Love SB et al. What do cancer patients mean when they complain of concentration and memory problems. Br J Cancer 1996; 74:1674–1679.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Schagen SB, Muller MJ, Boogerd W et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002; 13(9):1387–1387.

    Article  CAS  PubMed  Google Scholar 

  20. Tannock IF, Ahles TA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Onco 2004; 22:2233–2239.

    Article  Google Scholar 

  21. Jacobs SR, Jacobsen PB, Booth-Jones M et al. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic stem cell transplant patients. J Pain Symptom Manage 2007; 33(1):13–23.

    Article  PubMed  Google Scholar 

  22. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer 2002; 3(Suppl 3):S91–S99.

    Article  PubMed  Google Scholar 

  23. Wefel JS, Lenzi R, Theriault R et al. ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer 2004; 101:466–475.

    Article  PubMed  Google Scholar 

  24. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7(3):192–201.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Faust D, Fogel BS. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 1989; 177(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  26. Fogel BS. The high sensitivity cognitive screen. International Psychogeriatrics 1991; 3:273–288.

    Article  CAS  PubMed  Google Scholar 

  27. Erlanger DM, Feldman DJ, Kaplan D et al. Development and validation of the cognitive stability index, a Web-based protocol for monitoring change in cognitive function. Arch Clin Neuropsychol 2000; 15:693–694.

    Article  Google Scholar 

  28. Erlanger DM, Kutner KC, Jacobs AR. Hormones and cognition: Current concepts and issues in neuropsychology. Neuropsych Rev 1999; 9(4):175–207.

    Article  CAS  Google Scholar 

  29. Paraska KK, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncol Nurs Forum 2003; 30:473–478.

    Google Scholar 

  30. Schagen SB, van Dam FS, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640–650.

    Article  CAS  PubMed  Google Scholar 

  31. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210–218.

    Article  PubMed  Google Scholar 

  32. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res 2001; 50(2):86–94.

    Article  CAS  PubMed  Google Scholar 

  33. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94:828–834.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Kansas School of Nursing, 3901 Rainbow Blvd, Kansas City, Kansas, 66160, USA

    Jamie S. Myers

Authors
  1. Jamie S. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA

    Robert B. Raffa PhD

  2. Department of Pharmacology, Temple University School of Medicine, Phhiladelphia, Pennsylvania, USA

    Ronald J. Tallarida PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Myers, J.S. (2010). Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment. In: Raffa, R.B., Tallarida, R.J. (eds) Chemo Fog. Advances in Experimental Medicine and Biology, vol 678. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6306-2_9

Download citation

Publish with us

Policies and ethics

Search

Navigation